arroba Email

Have You Heard the Good News…

…about adult and umbilical cord blood stem cells? Probably not. Original Article

We have heard it stated so often it has become a media mantra: Embryonic stem cells (ESCs) offer the greatest hope for cures; adult and umbilical cord blood stem cells have far less potential; the Bush administration’s embryonic stem cell funding restrictions have caused America to fall behind in the great international race to develop effective ESC treatments.

Baloney, baloney, and pure baloney: The problems with harnessing embryonic stem cells as treatments appear to be growing, not shrinking. For example, ESC boosters used to claim that these cells are “immortal,” that is, they can be maintained indefinitely in culture to provide an inexhaustible source of cellular treatments. Well, not quite: Recent studies have demonstrated that over time ESC lines develop chromosomal abnormalities similar to those found in some cancers. This means that the useful shelf life of embryonic stem-cell lines is probably limited.

Moreover, the oft-heard assertion that ESCs can be used to create “any kind of cell in the body” remains poorly grounded scientifically. For such a bald assertion to be true, it would have to have been actually accomplished in repeated experiments. It hasn’t been. Few researchers have been able to differentiate an embryonic stem cell into the precise kind of cell they were seeking, and only that kind of cell. In most cases, attempts to morph ES cells into specific cell types have resulted instead in Petri dishes containing a wide variety of unwanted cells.

Animal experiments suggest that these proliferation difficulties may be the cause of the tumors so often seen when animals are injected with ESCs. This tendency to cause tumors is only one of the many problems that prevent researchers from using ESCs in human patients–problems widely expected to take many years to overcome, if they ever can be.

By contrast, the umbilical cord blood and adult stem-cell breakthroughs keep on coming. Human trials are ongoing for heart disease, spinal cord injury, eye afflictions, and many other diseases. And here’s a bit of potentially very big news: A just-published peer-reviewed study (Cytotherapy, Vol. 7. No. 4 (2005), 368-373) reports that scientists have used umbilical cord blood stem cells to restore feeling and mobility to a spinal cord injury patient. The patient had been paraplegic (complete paraplegia of the 10th thoracic vertebra) for 19 years. The researchers report that after receiving an infusion of umbilical cord blood stem cells,

[t]he patient could move her hips and feel her hip skin on day 15 after transplantation. On day 25 after transplantation her feet responded to stimulation. On post operative day (POD) 7, motor activity was noticed and improved gradually in her lumbar paravertebral and hip muscles. She could maintain an upright position by herself on POD 13. From POD 15 she began to elevate both lower legs about 1 cm, and hip flexor muscle activity gradually improved until POD 41.

In other words, she regained feeling and some mobility after nearly 20 years of being paralyzed. (Similar results for patients with spinal-cord injuries have been reported in human trials in Portugal using the patients’ own olfactory (nasal) stem cells–these studies have not yet been published in a peer-reviewed journal, though the very promising results in the first American patients have been testified to in a Senate subcommittee hearing and featured on the PBS television series Innovation.)

It is true that we have to be cautious about this. One apparently-helped paralyzed patient does not a broad efficacious treatment make. Also, the authors note that the woman also received a laminectomy (spinal surgery to release pressure) that could have provided her some benefit. Still, they report, not only did their patient regain feeling after years of numbness, but “41 days after [stem cell] transplantation” testing “also showed regeneration of the spinal cord at the injured site.” (emphasis added)

This is a wonderful story that offers tremendous hope for paralyzed patients and their families. But as is usually the case with-non embryonic stem-cell research breakthroughs, you could hear the crickets chirping at the New York Times and in most other mainstream media outlets. Indeed, these publications are more likely to publish stories about mouse experiments using ES cells than about promising human trials using adult or umbilical cord stem cells.

The same stunning silence has met other amazing adult stem cell research successes. For example, because it was shockingly underreported, most people do not know that Harvard researchers have cured mice with advanced juvenile diabetes using adult cells taken from the spleen. The experiment has been repeated and reported in Science, in one of the most prestigious peer-reviewed journals. It has proven so safe and effective that the FDA has approved moving to human trials. Unfortunately, the researchers cannot yet proceed because they don’t have sufficient funds.

When confronted with these and many other astonishing advances in non-embryonic research, ESC boosters defensively complain that ESC research has been stymied by President Bush’s federal funding limitations. Yet in 2003, the National Institutes of Health funded more than $20 million for ESC studies–with more funds available but not spent, due to the relative scarcity of qualified applications.

Opponents of the Bush policy counter that the Bush-approved ES cell lines aren’t good enough for effective use. But now, even this flimsy excuse is collapsing. Abundant state grant money is becoming available for embryonic stem-cell research (including research using new cell lines, and even newly created cloned embryos) in New Jersey and California. And guess what: As reported by the Newark Star Ledger, of 96 applications for state-funded stem-cell research grants in New Jersey, only one involved embryonic stem cells–and that request is for training funds, not bench science. The initial grants flowing out of Proposition 71 will also be primarily for training rather than actual research. Meanwhile, private investors generally avoid funding ESC research, primarily because they don’t see any chance of a return any time soon.

Talk about reality checks. For all the propaganda and hype boosting embryonic stem-cell research, ESCs are far from ready for prime time. Meanwhile, adult and umbilical cord blood stem-cell therapies keep quietly chugging along with continual advances in animal studies and the bringing of effective and safe treatments to a growing variety of suffering human patients. Maybe someday the media establishment will catch on to this real news, instead of focusing so myopically on the embryonic stem-cell story they want to tell.

Wesley J. Smith, is a senior fellow at the Discovery Institute and a special consultant for the Center for Bioethics and Culture. His current book is Consumer’s Guide to a Brave New World.

Wesley J. Smith

Chair and Senior Fellow, Center on Human Exceptionalism
Wesley J. Smith is Chair and Senior Fellow at the Discovery Institute’s Center on Human Exceptionalism. Wesley is a contributor to National Review and is the author of 14 books, in recent years focusing on human dignity, liberty, and equality. Wesley has been recognized as one of America’s premier public intellectuals on bioethics by National Journal and has been honored by the Human Life Foundation as a “Great Defender of Life” for his work against suicide and euthanasia. Wesley’s most recent book is Culture of Death: The Age of “Do Harm” Medicine, a warning about the dangers to patients of the modern bioethics movement.